Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Drugs
Published in: Drugs 10/2021

01-07-2021 | Lymphoma | AdisInsight Report

Loncastuximab Tesirine: First Approval

Author: Arnold Lee

Published in: Drugs | Issue 10/2021

Login to get access

Abstract

Loncastuximab tesirine (loncastuximab tesirine-lpyl; ZYNLONTA™) is an antibody-drug conjugate being developed for the treatment of B cell lymphomas by ADC Therapeutics SA. Loncastuximab tesirine consists of a pyrrolobenzodiazepine DNA-alkylating warhead covalently attached via a cleavable linker to an anti-CD19 antibody that binds to B cells. It is currently approved in the US for the treatment of relapsed/refractory diffuse large B cell lymphoma (DLBCL), and is being developed for the treatment of mantle-cell lymphoma, follicular lymphoma and acute lymphoblastic leukaemia. This article summarizes the milestones in the development of loncastuximab tesirine leading to this first approval for relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including DLBCL not otherwise specified (NOS), DLBCL arising from low grade lymphoma, and high-grade B-cell lymphoma.
Appendix
Available only for authorised users
Literature
1.
2.
Makita S, Tobinai K. Antibody therapy targeting CD19 for B-cell non-Hodgkin’s lymphoma. Ann Oncol. 2018;29(5):1086–9.CrossRef
3.
US Food & Drug Administration. FDA grants accelerated approval to loncastuximab tesirine-lpyl for large B-cell lymphoma [media release]. 23 Apr 2021. https://​www.​fda.​gov/​.
4.
ADC Therapeutics SA. ADC Therapeutics and Overland Pharmaceuticals announce formation of Overland ADCT BioPharma to develop and commercialize Lonca and other ADCs for hematologic and solid tumor indications in Greater China and Singapore [media release]. 14 Dec 2020. http://​www.​adctherapeutics.​com.
5.
6.
Auven Therapeutics. Auven Therapeutics announces AstraZenecas MedImmune acquires antibody-drug conjugate company Spirogen and invests in ADC Therapeutics [media release]. 15 Oct 2013. http://​www.​auventx.​com.
7.
Zammarchi F, Corbett S, Adams L, et al. ADCT-402, a PBD dimer-containing antibody drug conjugate targeting CD19-expressing malignancies. Blood. 2018;131(10):1094–105.CrossRef
8.
Hamadani M, Radford J, Carlo-Stella C, et al. Final results of a phase 1 study of loncastuximab tesirine in relapsed/refractory B-cell non-Hodgkin lymphoma. Blood. 2021;137(19):2634–45.CrossRef
9.
Depaus J, Wagner-Johnston ND, Zinzani PL, et al. Interim results of loncastuximab tesirine combined with ibrutinib in diffuse large B-cell lymphoma or mantle cell lymphoma (LOTIS-3) [abstract no. 2099 and presentation]. In: ASH 2020.
10.
Jain N, Stock W, Zeidan A, et al. Loncastuximab tesirine, an anti-CD19 antibody-drug conjugate, in relapsed/refractory B-cell acute lymphoblastic leukemia. Blood Adv. 2020;4(3):449–57.CrossRef
11.
12.
Metadata
Title
Loncastuximab Tesirine: First Approval
Author
Arnold Lee
Publication date
01-07-2021
Publisher
Springer International Publishing
Published in
Drugs / Issue 10/2021
Print ISSN: 0012-6667
Electronic ISSN: 1179-1950
DOI
https://doi.org/10.1007/s40265-021-01550-w

Other articles of this Issue 10/2021

Drugs 10/2021 Go to the issue

Review Article

Neurokinin-1 Antagonists for Postoperative Nausea and Vomiting

Correction

Correction to: Entrectinib: A Review in NTRK+ Solid Tumours and ROS1+ NSCLC

Letter to the Editor

Post-COVID-19 Syndrome: Leveraging the Patient Perspective and Technological Innovations to Enable the Delineation of Effective Treatments

Adis Drug Evaluation

Bupivacaine/Meloxicam Prolonged Release: A Review in Postoperative Pain

Review Article

Cholestatic Liver Disease: Current Treatment Strategies and New Therapeutic Agents

AdisInsight Report

Dostarlimab: First Approval